Discovery to translation
We measure and modify cortical excitability to improve the understanding and treatment of epilepsy and neurodevelopmental disorders.
We develop gene therapies for rare pediatric syndromes, including succinic semialdehyde dehydrogenase deficiency (SSADHD) and SLC6A1 neurodevelopmental disorder (SLC6A1-NDD). In parallel, we test novel anti-seizure compounds, including activators of the Kv3.1 voltage-gated potassium channel.
We use EEG and transcranial magnetic stimulation (TMS) to measure brain function and detect excitation–inhibition imbalance—or its restoration by gene and drug therapy.
We investigate how targeted neuromodulation approaches, including TMS and transcranial direct current stimulation (tDCS), can safely and effectively alter brain networks, particularly for seizure suppression.